Use of various immunotherapies for refractory ulcerative colitis in a person living with HIV: a case report.

ABSTRACT: Cancer therapies include several immune checkpoint or anticytokine therapies whereas ulcerative colitis treatments consist of anticytokine therapies. The development of tolerance and immunogical effects of these agents in people living with HIV are not well assessed as these persons are often excluded from clinical trials. Herein, we report a case of a Caucasian woman who received multiple sequential immunotherapies for severe ulcerative colitis. Due to steroid-refractory disease, receipt of maximal doses of mesalamine and initial repeated decline of surgical intervention, she went on to receive biologic immune inhibitors like tumor necrosis fator-α blockers infliximab and adalimumab, the α₄β₇integrin blocker vedolizumab, anti-interleukin 12/23 blocker ustekinumab and

SUBMITTER: Costiniuk CT 

PROVIDER: S-EPMC7846135 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature